• Title/Summary/Keyword: vaccine effect

Search Result 274, Processing Time 0.025 seconds

Development of a Quadrivalent Combined DTaP-HepB Vaccine with a Low Toxicity and a Stable HBsAg Immunogenicity

  • Bae, Cheon-Soon;Park, Kwung-Nam;Ahn, Sang-Jeom;Kim, Jong-Su;Hur, Byung-Ki
    • Journal of Microbiology and Biotechnology
    • /
    • v.12 no.5
    • /
    • pp.787-792
    • /
    • 2002
  • When developing a combined DTaP-HepB vaccine, toxicity and HBsAg immunogenicity are both important considerations. Thus, for a combined DTaP-HepB vaccine with a low toxicity, the effect of the DTaP content and $Al(OH)_3$, gel concentration on the vaccine toxicity was investigated. Within the range studied, the higher the concentrations, the higher the vaccine toxicity. The importance of the tetanus toxoid content in the combined DTaP-HepB vaccine was also revealed. A higher concentration of the tetanus toxoid was found to have a negative effect on the stability of the HBsAg immunogenicity in the combined vaccine. Accordingly, considering the factors affecting toxicity and HBsAg immunogenicity, a novel DTaP-HepB vaccine (30 Lf/ml of diphtheria toxoid, 5 Lf/ml of tetanus toxoid, 10 $\mu\textrm{g}$ PN/ml of acellular pertussis, 24 $\mu\textrm{g}$/ml of HBsAg, and 500 $\mu\textrm{g}$ Al/ml of $Al(OH)_3$ gel) was developed. It has a low toxicity and a stable HBsAg immunogenicity and also satisfies the potency criteria of K-FDA for a combined DTaP vaccine.

Effect of Information Characteristics of COVID-19 Vaccine on Acceptance Attitude Through Health Belief Theory

  • Lee, Sin-Bok
    • International Journal of Internet, Broadcasting and Communication
    • /
    • v.14 no.4
    • /
    • pp.20-35
    • /
    • 2022
  • COVID-19 vaccines have been developed worldwide in order to prevent the spread of coronavirus infection-19, but some people tend to refuse to be vaccinated against COVID-19. Therefore, we will investigate how people's understanding of COVID-19 vaccines affects their attitude to accept COVID-19 vaccination information. Therefore, the purpose of this study is to examine the determinants that affect the acceptability of COVID-19 vaccine through the informational characteristics of COVID-19 vaccine and the individual health belief theory. This study conducted an offline survey of 215 adult men and women living in Seoul and Gyeonggi-do Province during the period from September 1 to September 10, 2022, and we have conducted a final analysis using a total of 212 questionnaires. The results of our study were as follows. First, among the information characteristics of COVID-19 vaccine, it was confirmed that the amount of information had a significant positive effect on susceptibility, severity, and barriers in health belief theory, respectively. Second, among the information characteristics of COVID-19 vaccine, it was found that the quality of information had a significant positive effect on the susceptibility in health belief theory. Third, susceptibility and barriers in the health belief theory significantly had a positive effect on voluntary attitude and involuntary attitude in acceptance attitude, respectively. And finally, it was found that the severity of the health belief theory had a positive effect on the involuntary attitude in acceptance attitude. The results of this study suggest that policy efforts are needed to make accurate information about COVID-19 vaccine known to the people.

Effect of a trivalent (FPV, FHV, FCV) inactivated vaccine in kittens (고양이 3종(FPV, FHV, FCV) 불활화 백신의 효과)

  • Lee, Sung-min;Yoon, In-joong;Choi, Hwan-won;Lee, Keun-jwa;Lee, Kyoung-youl;Kim, Moo-kang
    • Korean Journal of Veterinary Research
    • /
    • v.45 no.3
    • /
    • pp.311-323
    • /
    • 2005
  • This study tested the effect of a trivalent (feline panleukopenia; FPV, feline viral rhinotracheitis; FHV, feline calicivirus infection; FCV) inactivated vaccine in cats. The vaccine was tested for the safety in guinea pigs, mice and cats. Also, it was tested for the efficacy in cats. The vaccine was inoculated to cats at 7~9 and 10~12 weeks of age (conventional schedule) and the serological response to vaccination was assessed and was compared to the unvaccinated group. All cats were bled by jugular venipuncture for FPV, FHV and FCV specific serological test (virus neutralizing antibody, VN) at 7~9, 10~12 and 13~15 weeks. After last bleeding, all cats were inoculated with each virus (FPV : orally $2ml\;10^{7.5}\;TCID_{50}/ml$, FHV : nasally $1ml\;10^{7.0}\;TCID_{50}/ml$ and FCV : nasally $1ml\;10^{7.0}\;TCID_{50}/ml$). The Vaccine verified excellent protective effect in guinea pigs, mice and cats. The VN antibody titers of the unvaccinated group cats against FPV, FHV and FCV were <2~16, on the other hand the vaccinated group cats were $512{\sim}{\geq}4096$, 64~1024 and 64~1024, respectively. When all cats were challenged with virulent viruses, the survival rates of the vaccinated group cats were over 80%, while the survival rates of the unvaccinated group cats were less 20%. The typical clinical signs were not observed in the vaccinated group cats, but the typical clinical signs and histopathological lesions were observed in the unvaccinated group cats. As the result of tests, the VN values obtained in this study appeared to be high enough to protect cats from viral challenges. The trivalent (FPV, FHV, and FCV) inactivated vaccine seemed to be very effective, for prevention of feline viral diseases (FPV, FHV, and FCV).

Assessment of Microorganism-derived Adjuvants for Scuticociliate Miamiensis avidus Vaccine (스쿠티카충Miamiensis avidus 주사백신용 미생물유래 면역보조제의 평가)

  • Jung, Myung-Hwa;Jung, Sung-Ju
    • Korean Journal of Fisheries and Aquatic Sciences
    • /
    • v.54 no.5
    • /
    • pp.652-659
    • /
    • 2021
  • Microorganism-derived compounds, such as peptidoglycan, lipoteichoic acid, and β-glucan were supplemented in the scuticociliate Miamiensis avidus (M. avidus) vaccine to verify the specify component contribution to the adjuvant effect. Vaccine was formulated with the inactivated M. avidus antigen (YS2, 4.44×105 cells/fish) in combination with either peptidoglycan (10 ㎍ and 100 ㎍/fish), lipoteichoic acid (5 ㎍ and 50 ㎍/fish), or β-glucan (10 ㎍ and 100 ㎍/fish). Olive flounder injected with peptidoglycan supplemented vaccine (10 ㎍ and 100 ㎍/fish) exhibited significant protection, and the relative percent survival (RPS) was 55% and 65% at 4 weeks post vaccination (wpv), respectively, at the corresponding doses. The vaccine groups with added lipoteichoic acid (5 ㎍ and 50 ㎍/fish) exhibited RPS of 40% and 5%, respectively. Additionally, the group with added β-glucan (100 ㎍/fish) exhibited RPS of 35%, but no effect was observed in the group with added 10 ㎍/fish β-glucan. At 8 wpv, olive flounder injected with peptidoglycan and lipoteichoic acid supplemented vaccines exhibited protection with RPS range of 11/11% and 5/21%, respectively, at the respective doses. M. avidus vaccine containing 10 ㎍ and 100 ㎍/fish of β-glucan exhibited the RPS of 32% and 37%, respectively. Conclusively, peptidoglycan contributed in high protection of the M. avidus vaccine, and thus, it can be used as an effective adjuvant in the M. avidus vaccine.

Quadrivalent Combined Vaccine, Including Diphtheria Toxoid, Tetanus Toxoid, Detoxified Whole Cell Pertussis, and Hepatitis B Surface Antigen

  • Bae, Cheon-Soon;Lim, Gwan-Yeul;Kim, Jong-Su;Hur, Byung-Ki
    • Journal of Microbiology and Biotechnology
    • /
    • v.13 no.3
    • /
    • pp.338-343
    • /
    • 2003
  • Various factors, such as the adsorption pH, adjuvant dose, and adjuvant age, which affect the adsorption degree and immunogenicity of an antigen, were investigated. In addition, the effect of pH, antigen content, and adjuvant content on immunogenicity was also studied through animal experiments. Within the ranges studied, a low pH for adsorption, freshly preformed gel, and low pH formulation for the combined DTwP-HepB vaccine were preferrable for the adsorption of the antigens. In addition, a higher DT content was found to have a positive effect on the HBsAg immunogenicity in the combined vaccine. Accordingly, considering the factors affecting the adsorption rate and immunogenicity of the antigens, a novel DTwP-HepB vaccine (40 Lf/ml of diphtheria toxoid, 15 Lf/ml of tetanus toxoid, 20 OU/ml of detoxified whole cell pertussis, $24\;\mu\textrm{g}$ of HBsAg, $24\;\mu\textrm{g}\;Al/ml\;of \;Al(OH)_3\;gel,\;776\;\mu\textrm{g}\; Al/ml\;of\;AIPO_4\;gel$, and pH 7.1) was developed, whose immunogenicity was comparable to the case of administrating, separately and simultaneously, a combined DTwP vaccine (40 Lf/ml of diphtheria toxoid, 15 Lf/ml of tetanus toxoid, 20 OU/ml of detoxified whole cell pertussis, $300\;\mu\textrm{g}\;Al/ml\;of\; AIPO_4\;gel$, and pH 7.1) and mono HepB vaccine [$Hepavax^{\circledR},\;24\;\mu\textrm{g}/ml$ of HBsAg and $500\;\mu\textrm{g}\;Al/ml\;of\;Al(OH)_3\;gel$], which satisfies the potency criteria of the K-FDA for a combined DTwP vaccine and mono HepB vaccine.

Effect of Addition of Sugar on the Stability of Hantaan Virus Vaccine (당첨가가 한탄바이러스백신의 안정성에 미치는 영향)

  • Seong, In-Wha
    • The Journal of Korean Society of Virology
    • /
    • v.26 no.2
    • /
    • pp.245-249
    • /
    • 1996
  • Hantaan virus vaccine was developed in 1988 and proved effective. This vaccine is a kind of inactivated vaccine, stable for two years when stored at $2-8^{\circ}C$. Almost virus vaccines including Hantaan virus vaccine are produced and kept in fluid state, and the immumogenicity can be easily destroyed at room temperature or at higher temperature. Therefore the vaccines should be kept in the refrigerator to maintain the immunogenicity. In this study, glucose and/or lactose was added as a stabilizer into Hantaan virus vaccine to increase the stability and dried in vaccum with ethanol treatment. 5% glucose and or lactose in Hantaan virus vaccine most effectively increased the stability of vaccine and maintained the immunogenicity at least for three months at room temperature. But drying with ethanol treatment did not help increasing the stability. These results suggest that glucose and lactose could be good stabilizer of virus vaccines.

  • PDF

Measurement of Free Polysaccharide in Tetanus Toxoid-Conjugate Vaccine Using Antibody/Ammonium Sulfate Precipitation

  • Yoo, Tae-Hyeon;Kim, Hyun-Sung;Park, Sung-Sik;Bang, Eun-Young;Oh, Yong-K.;Kim, Li-Seop;Kim, Hun;Hur, Byung-Ki;Ryu, Yeon-Woo;Kim, Jong-Su
    • Journal of Microbiology and Biotechnology
    • /
    • v.13 no.3
    • /
    • pp.469-472
    • /
    • 2003
  • A method that effectively precipitates capsular polysaccharide of Haemophilus influenzae type b (polyribosylribitol phosphate, PRP) conjugated to tetanus toxoid (TT), PRP TT in a liquid vaccine has been developed to measure free PRP present in TT-conjugate vaccine. The method involves adding anti-TT antibody and ammonium sulfate to precipitate PRP-TT conjugate and measuring free PRP in tile supernatant. This new method provides a complete precipitation of the total PRP-TT, and provides an accurate and reproducible measurements of free PRP. The accuracy of the assay was confirmed by spiking known amounts of unconjugated PRP to PRP-TT conjugate, and the new method was found to have no effect on free PRP while precipitating PRP-TT. The published acid precipitation method did not produce reproducible results due to incomplete precipitation of PRP-TT, especially when the vaccine is formulated in a salt-buffered solution.

Therapeutic effect of a TM4SF5-specific peptide vaccine against colon cancer in a mouse model

  • Kwon, Sanghoon;Kim, Young-Eun;Park, Jeong-A;Kim, Doo-Sik;Kwon, Hyung-Joo;Lee, Younghee
    • BMB Reports
    • /
    • v.47 no.4
    • /
    • pp.215-220
    • /
    • 2014
  • Molecular-targeted therapy has gained attention because of its high efficacy and weak side effects. Previously, we confirmed that transmembrane 4 superfamily member 5 protein (TM4SF5) can serve as a molecular target to prevent or treat hepatocellular carcinoma (HCC). We recently extended the application of the peptide vaccine, composed of CpG-DNA, liposome complex, and TM4SF5 peptide, to prevent colon cancer in a mouse model. Here, we first implanted mice with mouse colon cancer cells and then checked therapeutic effects of the vaccine against tumor growth. Immunization with the peptide vaccine resulted in robust production of TM4SF5-specific antibodies, alleviated tumor growth, and reduced survival rate of the tumor-bearing mice. We also found that serum levels of VEGF were markedly reduced in the mice immunized with the peptide vaccine. Therefore, we suggest that the TM4SF5-specific peptide vaccine has a therapeutic effect against colon cancer in a mouse model.

Anti-tumor Effect of 4-1BBL Modified Tumor Cells as Preventive and Therapeutic Vaccine

  • Hong Sung Kim
    • Biomedical Science Letters
    • /
    • v.28 no.4
    • /
    • pp.312-316
    • /
    • 2022
  • We have previously reported that genetically modified tumor cells with 4-1BBL have anti-cancer effects in a CT26 mouse colorectal tumor model. In this study, genetically modified tumor cells with 4-1BBL were evaluated for their potential as candidates for preventive and therapeutic cancer vaccine. To identify the effect of preventive and therapeutic vaccine of genetically modified tumor cells with 4-1BBL, tumor growth pattern of CT26-4-1BBL as a cancer vaccine was examined compared to CT26-beta-gal. In therapeutic vaccination, CT26-WT was inoculated into mice and then vaccinated mice with doxorubicin (Dox)-treated CT26-beta-gal and CT26-4-1BBL (single or three times). Triple vaccination with Dox-treated tumor cell inhibited tumor growth compared to single vaccination. Vaccination with CT26-4-1BBL showed an efficient tumor growth inhibition compared to vaccination with CT26-beta-gal. For preventive vaccination, Dox-treated CT26-beta-gal and CT26-4-1BBL was vaccinated into mice with three times and then administered mice with CT26-WT. Preventive vaccination with CT26-4-1BBL showed no tumor growth. Preventive vaccination with CT26-beta-gal also led to tumor-free mice. These results suggest that genetically modified tumor cells with 4-1BBL can be used as therapeutic or preventive cancer vaccine.

Immunomodulatory Effect of Auapuncture with Canine Parvovirus Vaccine (개 파보바이러스 백신 水針의 勉疫調節 효과)

  • 황수현;서지민;홍민성;최용수;송근호;김덕환;김명철;신광순
    • Journal of Veterinary Clinics
    • /
    • v.18 no.4
    • /
    • pp.368-373
    • /
    • 2001
  • To study the immunomodulatory effect of aquapuncture with canine parvovirus killed vaccine, the vaccine was inoculated into the dogs twice with on 2-week interval. The 6 dogs in the experimental group were inoculated through the Jiao-Chao acupoint, and 5 dogs in the control group were done subcutaneously. The antibody titer was determined by the hemagglutination inhibition test. The HI titers of the experimental group showed significantly higher on days 21 and 28 than those of the control group. The biochemical test on serum total protein, protein fractions and the A/G ration showed a slightly increased in $\gamma$-globulin on days 21 and 28. The hematological findings on total leukocytes and differential counts showed no significance. It was thought that the aquapuncture of the canine parvovirus killed vaccine through the Jiao-Cho acupoint may stimulate the antibody production.

  • PDF